Drugs / FP187
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02475304 | May 2015 → Oct 2016 | psoriatic arthritis | Skane University Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT01230138 | Sep 2010 → Jan 2012 | psoriasis | Forward-Pharma GmbH | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01815723 | Jun 2016 → Jun 2017 | psoriasis | Forward-Pharma GmbH | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FP187 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01230138 ↗ |
| Route | Oral | “Oral tablets, up to 3 times daily for 20 weeks.” NCT01230138 ↗ |